

# Nonclinical Safety Biomarkers of Drug-induced Vascula

Toxicologic Pathology

42, 635-657

DOI: [10.1177/0192623314525686](https://doi.org/10.1177/0192623314525686)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Regulatory Forum Opinion Piece*. Toxicologic Pathology, 2015, 43, 457-463.	0.9	9
2	The Far Side of Vascular Injury. Toxicologic Pathology, 2015, 43, 945-958.	0.9	1
3	Better Science with Human Cell-based Organ and Tissue Models. ATLA Alternatives To Laboratory Animals, 2015, 43, 29-38.	0.7	14
4	Scientific and Regulatory Policy Committee Points-to-consider Paper*. Toxicologic Pathology, 2015, 43, 915-934.	0.9	28
5	Temporal Patterns of Novel Circulating Biomarkers in IL-2-mediated Vascular Injury in the Rat. Toxicologic Pathology, 2015, 43, 984-994.	0.9	4
6	Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. Bioanalysis, 2015, 7, 229-242.	0.6	39
7	Scientific and Regulatory Policy Committee Points-to-consider Paper*. Toxicologic Pathology, 2015, 43, 935-944.	0.9	41
10	Naphthoquine-induced Central Nervous System and Hepatic Vasculocentric Toxicity in the Beagle Dog. Toxicologic Pathology, 2016, 44, 1128-1136.	0.9	2
11	Human Vascular Microphysiological System for in vitro Drug Screening. Scientific Reports, 2016, 6, 21579.	1.6	78
12	A bilayer small diameter <i>in vitro</i> vascular model for evaluation of drug induced vascular injury. Biomicrofluidics, 2016, 10, 054116.	1.2	5
14	Technological Advances in Cardiovascular Safety Assessment Decrease Preclinical Animal Use and Improve Clinical Relevance. ILAR Journal, 2016, 57, 120-132.	1.8	11
15	Noninvasive In Vivo Optical Imaging Models for Safety and Toxicity Testing. , 2016, , 305-317.		4
16	Immunopathology of the Cardiovascular System. Molecular and Integrative Toxicology, 2017, , 455-477.	0.5	0
17	Discover Toxicology: An Early Safety Assessment Approach. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 119-162.	0.2	2
18	Use of Rat Primary Mesenteric Cells for the Prediction of PDE4 Inhibitor Drug-Induced Vascular Injury. Toxicological Sciences, 2017, 159, 42-49.	1.4	0
19	Qualification of safety biomarkers for use in drug development: What has been achieved and what is the path forward?. Current Opinion in Toxicology, 2017, 4, 66-73.	2.6	2
20	Biomarkers in Nonclinical Drug Development. , 2017, , 447-471.		26
21	Species Differences in Renal Development and Associated Developmental Nephrotoxicity. Birth Defects Research, 2017, 109, 1243-1256.	0.8	26

#	ARTICLE	IF	CITATIONS
22	Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile. <i>MedChemComm</i> , 2017, 8, 771-779.	3.5	8
23	Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science. <i>Therapeutic Innovation and Regulatory Science</i> , 2018, 52, 244-255.	0.8	24
24	Vascular Cells and Tissue Constructs Derived from Human Pluripotent Stem Cells for Toxicological Screening. <i>Stem Cells and Development</i> , 2019, 28, 1347-1364.	1.1	2
25	Biomarkers of platelet dysfunction in non-clinical safety studies and humans. <i>Current Opinion in Toxicology</i> , 2019, 17, 41-49.	2.6	0
26	Evaluating Associations Between Nonclinical Cardiovascular Functional Endpoints and Repeat-dose Cardiovascular Toxicity in the Beagle Dog: A Cross-company Initiative. <i>Toxicological Sciences</i> , 2020, 176, 224-235.	1.4	3
27	Human Induced Pluripotent Stem Cells as a Screening Platform for Drug-Induced Vascular Toxicity. <i>Frontiers in Pharmacology</i> , 2021, 12, 613837.	1.6	6
28	Noninvasive in vivo optical imaging models for safety and toxicity testing. , 2021, , 363-377.		0
29	Cardiovascular microphysiological systems (CVMPS) for safety studies – a pharma perspective. <i>Lab on A Chip</i> , 2021, 21, 458-472.	3.1	6
30	The Predictive Safety Testing Consortium: safety bio-markers, collaboration, and qualification. <i>Journal of Medicines Development Sciences</i> , 2015, 1, 34.	0.1	16
31	Biomarkers of translational medicine. , 2018, 17, 6-13.	0.3	2
32	Pathology of the Cardiovascular System. , 2019, , 279-309.		0
33	Target sites: cardiovascular. , 2020, , 529-532.		0
34	Clinical Pathology in Nonclinical Toxicity Testing. , 2022, , 295-334.		1
35	Special Techniques in Toxicologic Pathology. , 2022, , 335-393.		1
36	Human Vascular Wall Microfluidic Model for Preclinical Evaluation of Drug-Induced Vascular Injury. <i>Tissue Engineering - Part C: Methods</i> , 2022, 28, 83-92.	1.1	1
37	Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies. <i>Toxicologic Pathology</i> , 2022, 50, 808-826.	0.9	1
38	Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies. <i>Veterinary Clinical Pathology</i> , 2022, 51, 311-329.	0.3	1
39	Detection of fenoldopam-induced arteritis in rats using ex vivo / in vivo MRI. <i>Toxicology Reports</i> , 2022, 9, 1595-1602.	1.6	1

#	ARTICLE	IF	CITATIONS
41	Evaluation of in vivo MRI for detecting midodrine-induced arteritis in rats. Toxicology Reports, 2023, 10, 97-103.	1.6	0
42	Biomarkers in Nonclinical Drug Development. , 2024, , 463-487.		0
43	Liver and Gall Bladder. , 2024, , 149-247.		0